Financials data is unavailable for this security.
View more
Year on year Merck & Co Inc 's net income fell -97.49% from 14.52bn to 365.00m despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 16.78% to 17.27%.
Gross margin | 75.79% |
---|---|
Net profit margin | 22.01% |
Operating margin | 24.75% |
Return on assets | 12.67% |
---|---|
Return on equity | 33.39% |
Return on investment | 16.42% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Merck & Co Inc fell by 5.86bn. However, the company earned 13.01bn from its operations for a Cash Flow Margin of 21.64%. In addition the company used 14.08bn on investing activities and also paid 4.81bn in financing cash flows.
Cash flow per share | 7.04 |
---|---|
Price/Cash flow per share | 16.65 |
Book value per share | 17.19 |
---|---|
Tangible book value per share | 2.14 |
More ▼
Balance sheet in USDView more
Current ratio | 1.47 |
---|---|
Quick ratio | 1.22 |
Total debt/total equity | 0.8671 |
---|---|
Total debt/total capital | 0.464 |
More ▼
Growth rates in USD
Year on year, growth in dividends per share increased 5.71% while earnings per share excluding extraordinary items fell by -97.49%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.
Div yield(5 year avg) | 2.84% |
---|---|
Div growth rate (5 year) | 8.26% |
Payout ratio (TTM) | 56.40% |
EPS growth(5 years) | -43.23 |
---|---|
EPS (TTM) vs TTM 1 year ago | 342.24 |
More ▼